Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Kura Oncology, Inc. incurred term loan of up to $125.0 million with Hercules Capital, Inc. at the greater of (i) the prime rate as reported in The Wall Street Journal minus 6 maturing the fifth anniversary of the Effective Date.
- Instrument
- term loan
- Principal
- up to $125.0 million
- Counterparty
- Hercules Capital, Inc.
- Rate
- the greater of (i) the prime rate as reported in The Wall Street Journal minus 6
- Maturity
- the fifth anniversary of the Effective Date
- Event
- incurrence
Exact text from the filing
the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders, pursuant to which the Lenders have agreed to make available to the Company up to $125.0 million in senior secured term loans (the “Term Loan Facility”), consisting of (i) an initial term loan of up to $25.0 million, $10.0 million of which was funded immediately after the Effective Date, (ii) two additional tranches of term loans in the amounts of up to $35.0 million (the “Tranche 2 Loan”) and $40.0 million (the “Tranche 3 Loan”), respectively, which will become available to the Company upon the Company’s satisfaction of certain terms and conditions set forth in the Loan Agreement, and (iii) a final tranche of term
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Kura Oncology, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. valued at Up to $125.0 million in senior secured term loans, with initial $10.0 million funded immediately aft (effective 2022-11-02).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc.
- Value
- Up to $125.0 million in senior secured term loans, with initial $10.0 million funded immediately aft
- Effective
- 2022-11-02
Exact text from the filing
Also on November 2, 2022 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders, pursuant to which the Lenders have agreed to make available to the Company up to $125.0 million in senior secured term loans (the “Term Loan Facility”), consisting of (i) an initial term loan of up to $25.0 million, $10.0 million of which was funded immediately after the Effective Date
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Kura Oncology, Inc. entered into Securities Purchase Agreement with Bristol-Myers Squibb Company valued at 1,370,171 shares of common stock at $18.2459 per share for gross proceeds of approximately $25.0 mil (effective 2022-11-02).
- Action
- entry
- Agreement
- license
- Counterparty
- Bristol-Myers Squibb Company
- Value
- 1,370,171 shares of common stock at $18.2459 per share for gross proceeds of approximately $25.0 mil
- Effective
- 2022-11-02
Exact text from the filing
On November 2, 2022, Kura Oncology, Inc. (“Kura” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Bristol-Myers Squibb Company (“BMS”).
View on SEC.gov